|
REPORT ABUSIVE MESSAGE
|
|
Subject
|
Japan approves COVID antibody cocktail used to treat Trump.Roche unit's offering holds promise as a tool against worsening cases
|
|
Poster Handle
|
christian |
|
Post Content
|
TOKYO -- An antibody cocktail developed by U.S.-based Regeneron Pharmaceuticals was granted special emergency approval by Japan's health ministry on Monday, opening up new opportunities to keep milder coronavirus cases from progressing and overwhelming health care providers on the ground.
Developed with Roche, the treatment was administered to then-U.S. President Donald Trump when he contracted COVID-19 last year. It received an emergency use authorization from the U.S. Food and Drug Administration that November.
Shipments to health care providers throughout Japan will begin Tuesday.
A clinical trial found that the cocktail reduced the risk of hospitalization or death by 70% in high-risk patients, according to Regeneron.
In addition, an Oxford University-sponsored trial on almost 10,000 patients found that it reduced mortality by a fifth and shortened hospitalizations by about four days among patients who previously had no coronavirus antibodies of their own. [ link to asia.nikkei.com (secure)]
|
|
|
Please verify you're human:
|
|
|
Reason for reporting:
|
